Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of rontalizumab in systemic lupus erythematosus
jRCT2080221821Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of rontalizumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
rontalizumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080221821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221821.